Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
TScan Therapeutics, Inc.TScan Therapeutics Reports Decline in Collaboration Revenue, Increased Operating Expenses in Q3 2024
Dyne Therapeutics, Inc.Dyne Therapeutics Reports Significant Asset Growth, Net Loss in Latest Quarter
FAMILY OFFICE OF AMERICA, INC.Qualis Innovations Reports Significant Financial Improvements, Net Loss Narrows in Latest 10-Q Filing
Maiden Holdings, Ltd.Maiden Holdings Reports Significant Net Loss and Revenue Decline in Q3 2024
SPRUCE BIOSCIENCES, INC.Spruce Biosciences Reports Financial Results, Implements Cost Reduction Measures, and Explores Additional Financing Options
ASSURED GUARANTY LTDAssured Guaranty Ltd. Reports Mixed Q3 2024 Results, Decline in Revenues and Adjusted Operating Income
Perimeter Solutions, Inc.Perimeter Solutions Reports 102% Net Sales Growth, Operating Loss in Q3 2024
reAlpha Tech Corp.reAlpha Tech Corp. Reports 475% Revenue Growth, Operating Losses in Latest Quarter
Vincerx Pharma, Inc.Vincerx Pharma Reports Significant Decrease in Cash and Cash Equivalents, Operating Expenses, and Net Loss
Lifeward Ltd.LifeWard Ltd. Reports 39% Revenue Growth, Narrowing Losses in Latest Quarter
WERNER ENTERPRISES INCWerner Enterprises Reports Decline in Revenue and Net Income for Q3 and Nine Months of 2024
HERON THERAPEUTICS, INC. /DE/Heron Therapeutics Reports Improved Revenue and Reduced Losses in Q3 2024
NEVRO CORPNevro Corp. Reports Decline in Revenue and Profitability for Q3 2024
FEMASYS INCFemasys Inc. Reports 127% Revenue Growth, Net Loss in Q3 2024
DZS INC.DZS Inc. Reports 67.8% Revenue Growth, Improved Profitability in Q3 2024
UFP TECHNOLOGIES INCUFP Technologies Reports 44% Revenue Growth in Q3 2024, Driven by Medical Market and Strategic Acquisitions
CervoMed Inc.CervoMed Reports Significant Net Loss and Increased Grant Revenue in Latest Quarter
Mineralys Therapeutics, Inc.Mineralys Therapeutics Reports Increased Cash Reserves, Rising Operating Expenses, and Net Loss in Latest Quarter
GILEAD SCIENCES, INC.Gilead Sciences Reports Mixed Q3 Results with Increased Revenues and Declining Profitability
Assertio Holdings, Inc.Assertio Holdings Reports Decline in Revenues, Improvement in Profitability in Q3 2024
SIEBERT FINANCIAL CORPSiebert Financial Reports Strong Revenue Growth and Improved Profitability in Q3 2024
Mirum Pharmaceuticals, Inc.Mirum Pharmaceuticals Reports Significant Revenue Growth and Strategic Acquisitions in Latest 10-Q Filing
Replimune Group, Inc.Replimune Group Reports Net Loss of $53.1 Million for Q2 2024, Improves Loss Per Share
Ovid Therapeutics Inc.Ovid Therapeutics Reports Modest Revenue Growth, Continued Net Losses in Q3 2024
Protara Therapeutics, Inc.Protara Therapeutics Reports Improved Financial Position, Advances Clinical Trials for Cancer and Rare Disease Treatments